AAAAAA

   
Results: 1-25 | 26-44
Results: 1-25/44
A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER
Authors: VALERO V BURRIS H JONES S EARHART R VONHOFF D HORTOBAGYI G
Citation: V. Valero et al., A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER, Annals of oncology, 9, 1998, pp. 66-66
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ET-743, A NOVEL MINOR-GROOVE BINDER OF MARINE ORIGIN ADMINISTERED ON A DAILY X 5 SCHEDULE
Authors: HIDALGO M VILLALONACALERO MA ECKHARDT SG WEISS G CAMPBELL E KRAYNAK M BEIJNEN J JIMENO J VONHOFF D ROWINSKY E
Citation: M. Hidalgo et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ET-743, A NOVEL MINOR-GROOVE BINDER OF MARINE ORIGIN ADMINISTERED ON A DAILY X 5 SCHEDULE, Annals of oncology, 9, 1998, pp. 613-613
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOLATE (MTA, LY231514) WITH FOLIC-ACID (FA)
Authors: HAMMOND L VILLALONACALERO M ECKHARDT SG SIU L HIDALGO M THORNTON D WALLING J BAKER S COLTMAN C VONHOFF D ROWINSKY E
Citation: L. Hammond et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOLATE (MTA, LY231514) WITH FOLIC-ACID (FA), Annals of oncology, 9, 1998, pp. 620-620
ANTITUMOR-ACTIVITY OF MGI-114 AGAINST 2 HUMAN PROSTATE TUMOR XENOGRAFT MODELS
Authors: MANGOLD G MACDONALD J VONHOFF D WEITMAN S
Citation: G. Mangold et al., ANTITUMOR-ACTIVITY OF MGI-114 AGAINST 2 HUMAN PROSTATE TUMOR XENOGRAFT MODELS, Annals of oncology, 9, 1998, pp. 141-141
ENHANCED ANTITUMOR-ACTIVITY OF MGI-114 IN COMBINATION WITH PACLITAXELOR TOPOTECAN AGAINST A HUMAN LUNG-TUMOR XENOGRAFT MODEL
Authors: MANGOLD G MACDONALD J VONHOFF D WEITMAN S
Citation: G. Mangold et al., ENHANCED ANTITUMOR-ACTIVITY OF MGI-114 IN COMBINATION WITH PACLITAXELOR TOPOTECAN AGAINST A HUMAN LUNG-TUMOR XENOGRAFT MODEL, Annals of oncology, 9, 1998, pp. 142-142
EFFECTS OF TEMOZOLOMIDE AGAINST HUMAN TUMOR USING THE HUMAN TUMOR CLONING ASSAY
Authors: RAYMOND E IZBICKA E SODA H GERSON S DUNGAN M VONHOFF D
Citation: E. Raymond et al., EFFECTS OF TEMOZOLOMIDE AGAINST HUMAN TUMOR USING THE HUMAN TUMOR CLONING ASSAY, Annals of oncology, 9, 1998, pp. 145-145
IN-VITRO ANTITUMOR EFFECTS OF OXALIPLATIN (OXPT) AGAINST HUMAN TUMOR USING THE HUMAN TUMOR CLONING ASSAY
Authors: RAYMOND E LAWRENCE R IZBICKA E FAIVRE S VONHOFF D
Citation: E. Raymond et al., IN-VITRO ANTITUMOR EFFECTS OF OXALIPLATIN (OXPT) AGAINST HUMAN TUMOR USING THE HUMAN TUMOR CLONING ASSAY, Annals of oncology, 9, 1998, pp. 147-147
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE
Authors: JOHNSON T GEYER C DEJAGER R ECKHARDT SG SMETZER L CLARK G COYLE J DRENGLER R VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE, Annals of oncology, 9, 1998, pp. 245-245
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF LU79553, A NOVEL BIS-NAPHTHALAMIDE ON A DAILY X 5 SCHEDULE
Authors: VILLALONACALERO M EDER J TOPPMEYER D ALLEN L VELAGAPUDI R MYERS M AMATO A KAGENHALLET K RAZVILLAS B OCONNOR L FRAM R KUFE D VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF LU79553, A NOVEL BIS-NAPHTHALAMIDE ON A DAILY X 5 SCHEDULE, Annals of oncology, 9, 1998, pp. 249-249
PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY
Authors: ROWINSKY E HAMMOND L AYLESWORTH C HUMPHREY R SMETZER L SIU L WEISS G SMITH L THURMAN A RODRIGUEZ G SORENSEN M VONHOFF D ECKHARDT SG
Citation: E. Rowinsky et al., PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY, Annals of oncology, 9, 1998, pp. 287-287
COMPARISON OF PROLONGED AND SHORT-TERM EXPOSURE PACLITAXEL (TAXOL(R))USING THE HUMAN TUMOR CLONING ASSAY
Authors: RAYMOND E FAIVRE S IZBICKA E CLARK G ROWINSKY E HANAUSKE A VONHOFF D
Citation: E. Raymond et al., COMPARISON OF PROLONGED AND SHORT-TERM EXPOSURE PACLITAXEL (TAXOL(R))USING THE HUMAN TUMOR CLONING ASSAY, Annals of oncology, 9, 1998, pp. 351-351
PHASE-I STUDY OF CAPECITABINE IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER
Authors: VILLALONACALERO M BLUM J DIAB S ELLEDGE R KHOURY P KRAYNAK M MOCZYGEMBA J KROMELIS P IMPELLIZERI K GRIFFIN T VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., PHASE-I STUDY OF CAPECITABINE IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER, Annals of oncology, 9, 1998, pp. 370-370
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS
Authors: DIAB S BAKER SD HAMMOND L VILLALONA M ECKHARDT SG TINU C WEISS G KRAYNAK M AYLESWORTH C SMITH L RODRIGUEZ G DRENGLER R PATIL R SIU L ROTHENBERG M SMETZER L NYHART E STORNIOLO AM VONHOFF D ROWINSKY E
Citation: S. Diab et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS, Annals of oncology, 9, 1998, pp. 440-440
PHASE-I AND PHARMACOKINETIC (PK) TRIAL OF SEQUENCES OF BCNU AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH SOLID NEOPLASMS
Authors: HAMMOND L ECKARDT J KUHN J RIZZO J JOHNSON T VILLALONACALERO M SMITH L DRENGLER R CAMPBELL L VONHOFF D ROWINSKY E
Citation: L. Hammond et al., PHASE-I AND PHARMACOKINETIC (PK) TRIAL OF SEQUENCES OF BCNU AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH SOLID NEOPLASMS, Annals of oncology, 9, 1998, pp. 441-441
A PHASE-I AND PHARMACOKINETIC STUDY OF ET-743, A NOVEL DNA MINOR-GROOVE BINDER OF MARINE ORIGIN, ADMINISTERED AS A 1-HOUR INFUSION DAILY X 5 DAYS
Authors: VILLALONACALERO M ECKHARDT SG WEISS G CAMPBELL E HIDALGO M KRAYNAK M BEIJNEN J JIMENO J VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., A PHASE-I AND PHARMACOKINETIC STUDY OF ET-743, A NOVEL DNA MINOR-GROOVE BINDER OF MARINE ORIGIN, ADMINISTERED AS A 1-HOUR INFUSION DAILY X 5 DAYS, Annals of oncology, 9, 1998, pp. 453-453
A NONCYTOTOXIC DOSE OF HYDROXYUREA REDUCES THE EXPRESSION OF DOUBLE-MINUTE EXTRACHROMOSOMAL DNA IN ASCITES FROM PATIENTS WITH ADVANCED OVARIAN CARCINOMAS
Authors: RAYMOND E FAIVRE S WEISS G MCGILL J DAVIDSON K IZBICKA E KUHN J ALFRED G CLARK G VONHOFF D
Citation: E. Raymond et al., A NONCYTOTOXIC DOSE OF HYDROXYUREA REDUCES THE EXPRESSION OF DOUBLE-MINUTE EXTRACHROMOSOMAL DNA IN ASCITES FROM PATIENTS WITH ADVANCED OVARIAN CARCINOMAS, Annals of oncology, 9, 1998, pp. 467-467
BREQUINAR IN COMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED MALIGNANCIES - A PHASE-I STUDY WITH PHARMACOKINETICS
Authors: BURRIS A RAYMOND E AWADA A KUHN J OROURKE J BRENTZEL J LYNCH W KING SY BROWN T VONHOFF D
Citation: A. Burris et al., BREQUINAR IN COMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED MALIGNANCIES - A PHASE-I STUDY WITH PHARMACOKINETICS, Annals of oncology, 9, 1998, pp. 479-479
IN-VITRO TELOMERASE INHIBITORS IN HUMAN CANCER MODELS USING A BIOTINYLATED-PRIMER EXTENSION ASSAY
Authors: RAYMOND E IZBICKA E SUN D SHARMA S SODA H MANGOLD G SILVAS E WINDLE B LAURENCE R DAVIDSON K VONHOFF D
Citation: E. Raymond et al., IN-VITRO TELOMERASE INHIBITORS IN HUMAN CANCER MODELS USING A BIOTINYLATED-PRIMER EXTENSION ASSAY, Annals of oncology, 9, 1998, pp. 536-536
A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS
Authors: STEPHENSON J BAKER SD AYLESWORTH C SIU L SIMMONS C SHARMA S SMITH L PROULX L MARSOLAIS C HUNT W VONHOFF D ROWINSKY E
Citation: J. Stephenson et al., A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS, Annals of oncology, 9, 1998, pp. 596-596
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID
Authors: AYLESWORTH C BAKER SD STEPHENSON J BRITTEN C MONROE P WALLING J JOHNSON R VONHOFF D ROWINSKY E
Citation: C. Aylesworth et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID, Annals of oncology, 9, 1998, pp. 610-610
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE
Authors: DIAB S BRITTEN C SMITH R ECKHARDT SG BAKER S HAMMOND L SIU L SHARMA S HIDALGO M AYLESWORTH C YOUNG R WONG L RAZVILLAS B KRAYNAK M DOUGLASS E VONHOFF D ROWINSKY E
Citation: S. Diab et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE, Annals of oncology, 9, 1998, pp. 611-611
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA)
Authors: HAMMOND L BAKER SD VILLALONACALERO M ECKHARDT SG DRENGLER R AYLESWORTH C JOHNSON T HIDALGO M RODRIGUEZ G DIAB S MONROE P THORNTON D JOHNSON R VONHOFF D ROWINSKY E
Citation: L. Hammond et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA), Annals of oncology, 9, 1998, pp. 612-612
A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION
Authors: JOHNSON T SCHWARTZ G MCCUNE D STEPHENSON J AYLESWORTH C HAMMOND L MONROE P THORNTON D VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION, Annals of oncology, 9, 1998, pp. 613-613
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF PN401 AS A RESCUE AGENT FOR ESCALATING DOSES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH CANCER
Authors: HIDALGO M VILLALONACALERO MA BRITTEN C SIU L DRENGLER R HAMMOND L DIAB S CAMPBELL E LOUIE A ONEIL J VONHOFF D ROWINSKY E
Citation: M. Hidalgo et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF PN401 AS A RESCUE AGENT FOR ESCALATING DOSES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH CANCER, Annals of oncology, 9, 1998, pp. 625-625
A COMPARISON OF CLINICAL PHARMACODYNAMICS OF DIFFERENT ADMINISTRATIONSCHEDULES OF ORAL TOPOTECAN (TPT, HYCAMTIN(R))
Authors: GERRITS C SCHELLENS J BURRIS H PLANTING A VANDERBURG M VANBEURDEN V LOOS W HUDSON I FIELDS S VONHOFF D VERWEIJ J
Citation: C. Gerrits et al., A COMPARISON OF CLINICAL PHARMACODYNAMICS OF DIFFERENT ADMINISTRATIONSCHEDULES OF ORAL TOPOTECAN (TPT, HYCAMTIN(R)), European journal of cancer, 33, 1997, pp. 1105-1105
Risultati: 1-25 | 26-44